Navigation Links
Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
Date:12/11/2008

SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. 11 /PRNewswire/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) recently indicated that the ongoing extension of the DURATION-1 study is appropriate to use as the basis for demonstrating comparability between intermediate-scale clinical trial material made in Alkermes' manufacturing facility, and commercial-scale drug product made at Amylin's manufacturing facility.

"Following feedback from FDA, we now have an appropriate pathway to demonstrate manufacturing comparability of exenatide once weekly. This is a very important step for the submission of exenatide once weekly," said Orville G. Kolterman, M.D., senior vice president, research and development at Amylin Pharmaceuticals. "We remain confident that our NDA submission is on track to be completed by the end of the first half of 2009."

Final acceptance of the comparability data is dependent upon DURATION-1 study extension results that are expected in early 2009.

DURATION Program Update

The overall DURATION clinical program, designed to demonstrate superiority of exenatide once weekly as compared to other medications in the treatment of type 2 diabetes, remains on track. The companies recently initiated DURATION-4, the fourth planned DURATION study. The DURATION-4 study examines exenatide once weekly as a monotherapy treatment compared to either metformin, a thiazolidinedione (TZD) or a dipeptidyl peptidase-4 (DPP-4) inhibitor. The double-blind study is expected to include a
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
2. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
3. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
4. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
5. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
6. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
7. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
8. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans
9. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
10. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Edwards Lifesciences Corporation (NYSE: EW ... and hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the ... have him on Edwards, board as we pursue our focused ... and CEO.  "Bob has provided a valuable perspective to our ...
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 ... it will release its second quarter 2015 financial results ... 2015.   In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
... , , , , , , BANGALORE, India ... unique strategy. This is based on the following,elements: , , ... Sino-Indian focus, - Flexible co-development model availability, ... Experience of early stage life science company product development, - ...
... , , CAMBRIDGE, Mass. , ... it has reached an agreement with the U.S. Food and Drug ... trial for Vascugel®, an investigational new drug for the prevention of ... Special Protocol Assessment (SPA) procedure. Pervasis expects to initiate the study ...
Cached Medicine Technology:Infinitus Clinical Research Consolidates- Sino-Indian CRO Enhances Core Capabilities 2Infinitus Clinical Research Consolidates- Sino-Indian CRO Enhances Core Capabilities 3Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 2Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 3Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 4
(Date:7/31/2015)... , ... July 31, 2015 , ... ... important workshop at its new True North Conference Center. The medical community, social ... the Jacksonville community may be more aligned in the effort to better understand ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today ... media, and VIPs at the 2015 Vans US Open of Surfing, July 25 through ... can claim “no added sugar” on the market, is a natural choice given the ...
(Date:7/31/2015)... ... , ... Ticket Down is a reliable source of authentic Hamilton tickets ... refreshing show on Broadway, look no further than Hamilton. This American musical is critically ... Circle Award, Drama Desk Award, Lucille Lortel Award, and New York Drama Critics’ Award. ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article published ... if they could reach a consensus on the steps that need to be taken ... group reached 90 percent consensus on a series of steps that each surgeon must ...
(Date:7/31/2015)... York, New York (PRWEB) , ... ... ... renowned trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence is ... July 28th, 2015 was well received with a 94% approval rating from ...
Breaking Medicine News(10 mins):Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2
... including Parkinson's, Alzheimer's, Diffuse Lewy body disease, and ... Most commonly they become symptomatic due to a ... case of Parkinson's it is dopamine. When the ... impaired, which occurs with oxidation, the eventual results ...
... to diagnose and many a times the diagnosis is ... emerging as a promising technique for early diagnosis of ... facilitating rapid amplification of small amounts of a genome ... Urology Congress in India. Presence of even one ...
... (PPA),is a common ingredient found in many non-prescription cough ... remedies increased the risk of stroke by 23 percent. ... says, "Case reports have linked exposure to PPA to ... ,A hemorrhagic stroke results when an artery wall ruptures ...
... of India has successfully undergone left knee joint replacement by ... "The operation, which started at around 10 a.m., was completed ... satisfaction," Dr. Ranawat said at a press briefing. ``He (Mr. ... now in the recovery room. He is not on any ...
... injectable contraceptive pill has been approved by the Food ... than 99 percent effective when women get the shot ... the pill., ,Lunelle is an alternative to another ... works Like many other birth control pills as it ...
... that more than two-thirds of births in Russia are marred ... clinic is suffering health problems. , ,The number of ... 30 percent last year, said Olga Frolova, head of the ... that the decline is due to the spread of heavy ...
Cached Medicine News:
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
The upper body blanket covers the upper torso, arms, neck, and head of the patient....
... system delivers cold air to the patient ... temperatures down to 10C. Cooling the body ... been used as a therapeutic tool, particularly ... hypothermia is now widely used as a ...
Medicine Products: